# FKBP5-CCL5 interaction promotes neuroinflammation and neuronal apoptosis in ischemic stroke by regulating the MAPK pathway and enhancing NET formation

**Authors:** Zhongchen Li, Tengkun Yin, Hongyang Guo, Zhenxing Liu, Peijian Wang, Chao Liu, Qingbo Wang, Meng Zhang, Yilei Xiao, Jiyue Wang, Jiheng Hao, Liyong Zhang

PMC · DOI: 10.3389/fimmu.2025.1609989 · 2025-09-30

## TL;DR

This study shows that FKBP5 and CCL5 interaction worsens brain injury in stroke by boosting inflammation and cell death through the MAPK pathway and NET formation.

## Contribution

The study reveals a novel mechanism involving FKBP5-CCL5 interaction in promoting neuroinflammation and neuronal apoptosis via the MAPK pathway and NET formation in ischemic stroke.

## Key findings

- FKBP5 upregulation in stroke patients correlates with increased NET markers and disease severity.
- Inhibiting NETs with CI-amidine reduced brain injury and infarct size in a mouse stroke model.
- FKBP5 promotes M1 microglial polarization and pro-inflammatory cytokine production via CCL5 and the MAPK pathway.

## Abstract

The pathophysiology of ischemic stroke is not fully elucidated. Upregulation of FKBP5 in brain ischemia/reperfusion injury has been found to be associated with the severity of ischemic and reperfusion damage. However, its specific role in ischemic stroke progression remains unclear.

A total of 40 ischemic stroke patients and 40 age- and sex-matched healthy donors (HDs) were enrolled in this work to evaluate the expression of FKBP5, the formation of neutrophil extracellular trap (NET), and the correlation between NET and stroke. Moreover, transient middle cerebral artery occlusion (tMCAO) mouse model with 60 min occlusion (n = 15/group) was treated with CI-amidine to demonstrate the effect of NET on the stroke-related brain injury. Primary neurons were isolated from mouse brain tissue to evaluated the effect of NET on neuronal apoptosis through flow cytometry the TUNEL assays. In addition, BV2 microglial cells were transfected with FKBP5 overexpression and knockdown vectors. The microglial cells polarization, neutrophil NETs formation, and the underlying molecular action mechanism were measured. For specific methods: detected the levels of H3cit, MPO-DNA, IL-1β, IL-10, TNFα, and iNOS by ELISA; Pathological staining was viewed for the neuronal morphological changes; flow cytometry and TUNEL staining were viewed for the neuronal cell apoptosis; detected the protein levels of FKBP5, CD206, CCL5, and MAPK pathway by western blot.

In this study, we observed significant upregulation of FKBP5 in ischemic stroke patients, which was associated with increased expression of NET markers, such as H3cit and MPO-DNA complexes. This upregulation correlated with stroke severity and outcomes. In a transient middle cerebral artery occlusion (tMCAO) mouse model, treatment with the NET inhibitor CI-amidine significantly reduced brain injury, infarct size, and NET marker levels, suggesting therapeutic potential in targeting NETs. We further found that FKBP5 modulates microglial polarization towards a pro-inflammatory M1 phenotype and promotes NET formation. FKBP5 interacts with CCL5, enhancing MAPK pathway activation and increasing pro-inflammatory cytokine production, including TNF-α and IL-1β. Intervention with the MAPK pathway inhibitor AZD6244 effectively inhibited these effects.

The current findings suggest that FKBP5 might modulate CCL5-mediate p38 MAPK signaling and NET formation, thereby contributing to post-stroke neuroinflammation and neuronal apoptosis. Further prospective research is needed to verify the potential of FKBP5 as therapeutic targets for ischemic stroke treatment.

## Linked entities

- **Genes:** FKBP5 (FKBP prolyl isomerase 5) [NCBI Gene 2289], CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352], MRC1 (mannose receptor C-type 1) [NCBI Gene 4360]
- **Proteins:** FKBP5 (FKBP prolyl isomerase 5), CCL5 (C-C motif chemokine ligand 5), MAPK (mitogen activated kinase-like protein), IL1B (interleukin 1 beta), IL10 (interleukin 10), TNF (tumor necrosis factor), NOS2 (nitric oxide synthase 2)
- **Chemicals:** AZD6244 (PubChem CID 10127622)
- **Diseases:** ischemic stroke (MONDO:1060198)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Fkbp5 (FK506 binding protein 5) [NCBI Gene 14229] {aka D17Ertd592e, Dit1, FKBP-5, FKBP51}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, Ccl5 (C-C motif chemokine ligand 5) [NCBI Gene 20304] {aka MuRantes, RANTES, SISd, Scya5, TCP228}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Mpo (myeloperoxidase) [NCBI Gene 17523] {aka mKIAA4033}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}
- **Diseases:** ischemic stroke (MESH:D002544), infarct (MESH:D007238), middle cerebral artery occlusion (MESH:D020244), ischemic and reperfusion damage (MESH:D015428), neuroinflammation (MESH:D000090862), brain injury (MESH:D001930), brain ischemia (MESH:D002545), reperfusion injury (MESH:D015427), stroke (MESH:D020521), inflammatory (MESH:D007249)
- **Chemicals:** AZD6244 (MESH:C517975), CI-amidine (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** BV2 — Mus musculus (Mouse), Transformed cell line (CVCL_0182)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12518073/full.md

---
Source: https://tomesphere.com/paper/PMC12518073